Bill Newell is a lawyer turned large molecule wrangler. He’s CEO of Sutro Biopharma, and their special sauce - literally - lets them manipulate and manufacture antibodies with the kind of control scientists have had over small molecules for decades.

Where other biotechs find scientific challenges can threaten their survival, with Sutro it comes down to strategic challenges. And Bill has led them to enviable partnerships, capital, and optionality.

Sutro has an unfair advantage: Bill Newell.